In drug development, most narratives hinge on averages—median survival times, mean biomarker expression, or standard response rates. Yet, breakthroughs

In startups, we talk a lot about vision. Less about volume. But execution—unglamorous, cumulative, occasionally boring—is what actually

There’s a certain kind of book that masquerades as a memoir but is, in fact, a manifesto. Will Guidara’

In the grand cycle of corporate life, the pharmaceutical industry has mastered the art of layoffs while keeping its bottom

Founders, let’s address a pervasive issue in biotech: the chronic neglect of financial metrics in pitch decks. Investors aren’

Michael Lewis has made a career of peering behind the velvet curtain of capitalism and calmly announcing: “It’s mostly

The concepts of fat-tailed distributions and black swan events, as popularized by Nassim Nicholas Taleb in seminal work "The

Drug discovery operates at the intersection of science, technology, and uncertainty. Despite advances in high-throughput screening, computational modeling, and clinical

If you’ve read this blog—ramblings, thought-leadership, or the digital equivalent of shouting into the void—you might be

1. Pricing and Reimbursement Pressures 1.1 Early Pricing Negotiations * The New Reality: * Payers and HTA bodies, particularly in Europe,